Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast

Semir Vranic, Caterina Marchiò, Isabella Castellano, Cristina Botta, Maria Stella Scalzo, Ryan P. Bender, Cesar Payan-Gomez, Ludovica Verdun Di Cantogno, Patrizia Gugliotta, Fabrizio Tondat, Paola Francia Di Celle, Sara Mariani, Zoran Gatalica, Anna Sapino

    Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

    22 Citas (Scopus)

    Resumen

    Summary Despite the marked improvement in the understanding of molecular mechanisms and classification of apocrine carcinoma, little is known about its specific molecular genetic alterations and potentially targetable biomarkers. In this study, we explored immunohistochemical and molecular genetic characteristics of 37 invasive apocrine carcinomas using immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), multiplex ligation-dependent probe amplification (MLPA), and next-generation sequencing (NGS) assays. IHC revealed frequent E-cadherin expression (89%), moderate (16%) proliferation activity [Ki-67, phosphohistone H3], infrequent (~10%) expression of basal cell markers [CK5/6, CK14, p63, caveolin-1], loss of PTEN (83%), and overexpression of HER2 (32%), EGFR (41%), cyclin D1 (50%), and MUC-1 (88%). MLPA assay revealed gene copy gains of MYC, CCND1, ZNF703, CDH1, and TRAF4 in 50% or greater of the apocrine carcinomas, whereas gene copy losses frequently affected BRCA2 (75%), ADAM9 (54%), and BRCA1 (46%). HER2 gain, detected by MLPA in 38% of the cases, was in excellent concordance with HER2 results obtained by IHC/FISH (κ = 0.915, P <.001). TOP2A gain was observed in one case, while five cases (21%) exhibited TOP2A loss. Unsupervised hierarchical cluster analysis revealed two distinct clusters: HER2-positive and HER2-negative (P =.03 and.04, respectively). NGS assay revealed mutations of the TP53 (2 of 7, 29%), BRAF/KRAS (2 of 7, 29%), and PI3KCA/PTEN genes (7 of 7, 100%). We conclude that morphologically defined apocrine carcinomas exhibit complex molecular genetic alterations that are consistent with the "luminal-complex" phenotype. Some of the identified molecular targets are promising biomarkers; however, functional studies are needed to prove these observations.

    Idioma originalInglés estadounidense
    Páginas (desde-hasta)1350-1359
    Número de páginas9
    PublicaciónHuman Pathology
    Volumen46
    N.º9
    DOI
    EstadoPublicada - sep 1 2015

    All Science Journal Classification (ASJC) codes

    • Patología y medicina forense

    Huella

    Profundice en los temas de investigación de 'Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast'. En conjunto forman una huella única.

    Citar esto